PHAXIAM Therapeutics develops antibacterial treatments based on the use of bacteriophage viruses to combat bacterial infections, particularly those resistant to antibiotics. The company addresses antimicrobial resistance, which is a major global health issue.

PHAXIAM Therapeutics

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

COM:ERYTECH

PHAXIAM Therapeutics

Last Close

0.80

28/06 15:35

Market Cap

48.66M

Beta: -

Volume Today

27.49K

Avg: -

Analysis Not Available